Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$64.29M-23.2%$59.41M+53.3%$51.79M+41.1%$41.95M-6.8%$83.66M-0.1%
$220.96M-19.3%$241.42M+59.9%$252.33M$266.75M$273.68M
$2.07M-13.5%$2.23M-9.8%$2.14M$2.25M$2.39M
$73.78M-13.2%$74.42M+263%$76.67M$74.7M$85.02M
$305.04M-17.5%$325.95M+75.5%$339.27M$352.05M$369.67M
$2.11M-58.0%$769K-35.2%$1.48M+184%$914K$5.02M+201%
$9.78M+2.6%$11.71M+12.4%$9.85M$7.55M$9.53M
$16.83M-6.0%$19.12M+0.1%$17.6M$15.62M$17.91M
500M0.0%500M+9,999,900%500M500M500M
-$283.13M-43.3%-$256.35M-41.6%-$235.91M-$215.64M-$197.57M
$288.21M-18.1%$306.83M+287%$321.67M+317%$336.43M+351%$351.77M+379%
$305.04M-17.5%$325.95M+75.5%$339.27M$352.05M$369.67M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Sionna Therapeutics, Inc. Common Stock cover its short-term obligations?
Its current ratio is 22.60 — current assets exceed current liabilities.
Where does Sionna Therapeutics, Inc. Common Stock's balance sheet data come from?
Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.